Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Anti-cancer prodrug can benefit cancer patients

Unlike conventional cancer drugs that attack and kill cancer cells directly, anti-cancer immunotherapy, which kills cancer cells by strengthening the body's immunity, is a novel type of cancer treatment currently attracting increased attention. Unfortunately, a minority of cancer patients who have some degree of pre-existing immunity only benefit from anti-cancer immunotherapy.

28 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

The Role of Nanoparticles for Drug Delivery

In this interview, Mark Bumiller, Technology Manager at Entegris talks to News Medical Life Sciences about the role nanoparticles can play in drug delivery.

From Entegris 15 Jun 2021

Cdkn1a transcript variant 2 is selectively elevated during natural aging across mouse tissues

Aging published "Cdkn1a transcript variant 2 is a marker of aging and cellular senescence" which reported that cellular senescence is a cell fate response characterized by a permanent cell cycle arrest driven primarily the by cell cycle inhibitor and tumor suppressor proteins p16Ink4a and p21Cip1/Waf1.

3 Jun 2021

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

The cover for issue 7 of Oncotarget features Figure 5, "SUM149-MA cells surviving a 6-MP treatment are sensitive to chemotherapeutic drugs," published in "Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine" by Singh, et al. which reported that the authors have reported that a lengthy treatment with low-dose 6-mercaptopurine, a clinically useful anti-inflammatory drug, inhibits such resistant cells.

19 May 2021

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP—the standard treatment regimen.

8 Mar 2021

Researchers study the digestion process of drug-loaded DNA nanostructures in real time

DNA nanotechnology - the research field using DNA molecules as building material - has developed rapidly during recent years and enabled the construction of increasingly complex nanostructures.

2 Mar 2021

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy, and their combinations.

24 Feb 2021

New gut microbiome-based approach may have translational potential for cancer immunotherapy

Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

11 Feb 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

Heat treatment during chemotherapy is more effective at destroying cancer cells

Heating up cancer cells while targeting them with chemotherapy is a highly effective way of killing them, according to a new study led by UCL researchers.

5 Jan 2021

Low-intensity pulsed ultrasound combined with microbubbles might enhance chemotherapy delivery

Application of low-intensity pulsed ultrasound in combination with microbubbles might enhance the delivery of chemotherapy medication used for treating cancers.

17 Dec 2020

Researchers use new method to deliver anti-cancer drug to suppress tumor growth

Targeting drugs to cancer tissues is a major challenge in cancer treatment. Mesenchymal stem cells (MSCs) are known for their ability to find and target tumor cells in the body, but using MSCs for drug delivery has been tricky, because upon loading with drugs, MSCs lose their viability and migratory ability.

17 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.

From Avacta Life Sciences Ltd. 24 Nov 2020

A DNA-based nanogel for targeted delivery of therapeutics

Current chemotherapy regimens slow cancer progression and save lives, but these powerful drugs affect both healthy and cancerous cells.

18 Nov 2020

A promising vaccine for treating poorly immunogenic tumors

Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not effectively prevent tumor metastasis or disease recurrence.

11 Nov 2020

Novel 3D-printed scaffold loaded with chemotherapy drug could reduce breast cancer recurrence

The recurrence of cancer after surgery is a major concern for patients. New findings from a QUT study have shown the potential for a novel 3D-printed porous scaffold which is loaded with a common chemotherapy drug that can reduce breast cancer recurrence in an experimental setting.

10 Nov 2020

Nanoparticles release bursts of calcium to reverse multidrug resistance in tumor cells

Multidrug resistance (MDR) -- a process in which tumors become resistant to multiple medicines -- is the main cause of failure of cancer chemotherapy.

16 Oct 2020